All articles tagged with #health policy
The Trump administration proposed relaxing some federal restrictions on testosterone prescriptions, aiming to help men with low testosterone—thought to contribute to various health issues—access a range of therapies, from nasal gels to injections, amid ongoing debate about whether boosting testosterone can truly address aging-related health problems.
A BuzzFeed News piece gathers Reddit discussions and user anecdotes to explore how GLP-1 medications (like Ozempic, Wegovy, and Mounjaro) could reshape society over 20 years. Predictions span obesity becoming a “disease of poverty,” shifts in beauty standards toward muscle or other traits, and the role of patent expirations and pricing in global access. The article also highlights potential economic and geopolitical effects, factory shifts in the food and insurance industries, and debates over long‑term health impacts and craving dynamics, all illustrating a future where widespread GLP-1 use could alter health, wealth, and culture.
Robert F. Kennedy Jr. is pushing to overhaul the U.S. Preventive Services Task Force to expand coverage for preventive tests (including Alzheimer’s screening), prompting lobbying from test makers and patient groups while raising concerns among experts that expanding coverage could erode the task force’s evidence-based approach and boost insurance costs.
Medicare’s one-year Bridge Program now covers GLP-1 weight-loss medications (Foundayo, Wegovy, or Zepbound) for a $50 copay, extending access beyond diabetics to those with BMI 35+ or 27+ with conditions. The move could be a watershed for obesity treatment and trigger broader economic and policy shifts as demand and costs rise.
Medicare launches an 18-month GLP-1 Bridge program outside Part D to offer eligible beneficiaries $50-a-month copays for certain weight‑loss drugs (Foundayo tablets, Wegovy, Zepbound) ending Dec 31, 2027. Eligibility is based on BMI and specific health conditions, and prescriptions can be issued even if the doctor doesn’t take Medicare, but some diabetics and individuals with sleep apnea or fatty liver may still face higher costs under Part D. Medicare covers about $245 of the drug cost minus the $50 copay, potentially leaving a total outlay of up to roughly $900 over 18 months for a participant, with no low-income subsidy. Total taxpayer cost is projected at $1.3 billion to $10 billion depending on uptake. The program could boost access but may strain clinics and lacks long-term funding certainty.
An op-ed argues the new federal Lyme plan could validate misdiagnoses by steering patients to ILADS clinicians and framing Lyme as an infection-associated chronic illness, despite evidence that many positive tests (like isolated IgM or non-specific Western blots) are false and that genuine Lyme disease is geographically concentrated; the piece warns that long antibiotic courses can harm patients and calls for careful, evidence-based diagnosis instead of expanding a system built around a disputed syndrome.
Medicare has started covering certain GLP-1 weight-loss medications with a $50 copay, outlining which drugs are included and the eligibility criteria for beneficiaries. The policy aims to expand access to obesity treatments from manufacturers like Novo Nordisk and Eli Lilly, though coverage may depend on clinical indications and program details.
Medicare proposes hospitals begin recording adults’ end-of-life care preferences (including DNR orders and designated decision-makers) in electronic health records by 2028, with these preferences part of quality metrics that could affect reimbursements from 2030. The goal is to normalize advance care planning and reduce unwanted, costly interventions, though providers warn about added burden and studies show mixed effects on care and outcomes.
A federal judge blocked five states from enforcing waivers that would have prohibited SNAP purchases of sugary drinks and candy, ruling the USDA lacked authority to approve such pilot restrictions. The decision, while addressing legality rather than policy merit, stops the bans for now and underscores the regulatory guardrails governing SNAP.
The FDA announced a pilot to accelerate early-stage clinical trials, aiming to cut development time by six to 12 months, boost U.S.-based trials, and counter China, while seeking congressional support to establish a permanent, faster Investigational New Drug pathway in the 2027 budget; the effort follows advocacy by former FDA Commissioner Marty Makary.
US health officials want updated labeling for testosterone replacement therapy to reflect newer evidence that cardiovascular risks may be smaller than once feared, potentially easing access for older men; the TRAVERSE trial showed no excess major cardiac events but higher rates of atrial fibrillation and pulmonary embolism, and experts remain divided on prostate cancer risk, with labeling suggestions to limit use in metastatic cases and require ongoing monitoring for benign prostatic hyperplasia.
In a joint open letter issued at the G7 Summit, President Lula and WHO Director-General Tedros urge leaders to finalize the WHO Pandemic Agreement’s Pathogen Access and Benefit-Sharing annex by the July session, arguing that political will, equity, and urgency are essential for the treaty to enter into force; they emphasize sovereignty remains intact, warn that delaying would raise avoidable health and economic costs, and note negotiations resume July 6–17 to close remaining gaps and speed access to vaccines and treatments born from shared pathogens.
CMS has finalized work rules for certain Medicaid enrollees, affecting about 18.5 million people in expansion populations. Exemptions apply to children, pregnant people, those already receiving Social Security disability benefits, and medically frail individuals, though documentation and state decisions may tighten protections. Initially, states can rely on automated data or self-attestation; later, more proof may be required. Qualifying activities include 80 hours of work per month or alternatives like college enrollment, volunteering, or in-kind work. States must inform enrollees by mail or digital means, and rollout begins in January 2027 (with some states launching earlier). Enrollees should update contact info and check with their state Medicaid agency for specifics, as missteps could lead to coverage loss.
A 32-year-old Brazilian woman died after a state AI system for bed allocation allegedly scored her condition too low, delaying ICU transfer by five days; her family says the inflexible Core-MG system reduced clinician autonomy, while officials maintain transfers are based on bed availability and that Core-MG does not change transfer protocols.
The CMS has issued final Medicaid work rules targeting expansion enrollees, requiring 80 hours of qualifying activities per month (work, college courses, volunteering, or in‑kind work) with exemptions for children, pregnant people, and those who are medically frail or on Social Security disability. Initially, enrollees can self-attest and states will use available data to verify activity, but proof may later be required. The rules launch in most states by January 2027, with some states starting sooner; Arkansas, Nebraska, and Montana have noted phased approaches. While the aim is to curb fraud and extend coverage to those in need, there are concerns about administrative burden and potential loss of coverage for those unable to prove participation. Enrollees should update addresses and monitor state Medicaid notices for updates.